1.800.KIDS DOC | 1.800.543.7362

Susanna McColley, MD

Susanna McColley, MD

Associate Clinical Director for Child Health, Translational Sciences Institute, Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Associate Chief Research Officer for Clinical Trials and Director, Clinical and Translational Research, Stanley Manne Children’s Research Institute

Appointments & Referrals

1.800.543.7362 (1.800.KIDS DOC)

About Me

Clinical Interests: Cystic fibrosis, chronic cough, asthma, tobacco prevention and cessation

Specialties, Programs & Conditions

Specialties:

Pulmonary Medicine

Programs & Conditions:

Cystic Fibrosis Center

Education & Training

Education: Northwestern University, 1985

Postgraduate Training: Fellowship in pulmonology, Johns Hopkins Hospital, 1988-1991; Residency in pediatrics, Johns Hopkins Hospital, 1985-1988

Board Certifications: Pediatric Pulmonology

Professional Organizations: American Academy of Pediatrics; American College of Chest Physicians; American Thoracic Society

Research

Research Interests: Cystic fibrosis; pediatrics; pulmonary disorders

Publications

Most recent publications

Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights Genes (Basel)10 (3):
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study Lancet Respir Med
Identification of molecular signatures of cystic fibrosis disease status using plasma-based functional genomics Physiol Genomics
Cystic fibrosis year in review 2017 Pediatr Pulmonol53 (9): 1307-1317
Designing trials for new cystic fibrosis modulators Lancet Respir Med6 (7): 484-486
Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review Int J Eat Disord51 (3): 187-213
The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype J Cyst Fibros17 (1): 34-42
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis Expert Opin Drug Saf16 (11): 1305-1311
Cystic fibrosis year in review 2016 Pediatr Pulmonol52 (8): 1092-1102
Risk factors for mortality before age 18 years in cystic fibrosis Pediatr Pulmonol52 (7): 909-915

Call for Insurance information: 1.800.543.7362

News

3 Results

Cystic Fibrosis Drug Combo Found Safe and Effective for 2-5 Years Olds

Cystic Fibrosis Drug Shows Promise in Children as Young as 1 Year of Age

Study Describes the Good and Bad Lung Bacteria in Cystic Fibrosis Patients

See all News & Stories >